Nurix Therapeutics (NRIX) Cash from Investing Activities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash from Investing Activities data on file, last reported at $93.0 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 30.07% year-over-year to $93.0 million in Q2 2026; TTM through May 2026 was $20.0 million, a 130.7% increase from a year earlier, with the FY2025 full-year figure at $147.9 million, up 157.37% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at $93.0 million, up from -$123.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for NRIX reached as high as $93.0 million in Q2 2026 and fell as low as -$140.8 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged -$2.5 million across 5 years, with a median of $19.4 million in 2023.
• Across the five-year window, Cash from Investing Activities surged 1777.04% in 2022 and plunged 879.73% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $55.0 million in 2022, then sank by 126.13% to -$14.4 million in 2023, then plunged by 879.73% to -$140.8 million in 2024, then jumped by 100.25% to $346000.0 in 2025, then surged by 26777.75% to $93.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $93.0 million in Q2 2026, -$123.8 million in Q1 2026, and $346000.0 in Q4 2025.